Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice.
Several lines of evidence implicate dysfunction of glutamatergic neurotransmission in opiate dependence and withdrawal. Functional antagonists of glutamatergic system, including compounds acting on both ionotropic and metabotropic glutamate receptors (group I mGlu receptor antagonists and group II mGlu receptor agonists), have been shown to decrease behavioural signs of opiate withdrawal in rodents. In the present study we analyzed an influence of group III mGlu receptor agonist, ACPT-I, on opioid withdrawal syndrome, induced by repeated morphine administration and final naloxone injection. We show, that ACPT-I significantly attenuated typical symptoms of naloxone-induced morphine withdrawal, after peripheral administration in C57BL/6J mice. These data indicate an important role of group III mGlu receptors in morphine withdrawal states and suggest that activation of group III mGlu receptors may reduce opiate withdrawal symptoms.
Pałucha-Poniewiera
Agnieszka
A
Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343 Kraków, Poland. nfpaluch@cyf-kr.edu.pl
Novák
Kinga
K
Pilc
Andrzej
A
D000704:Analysis of Variance; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003517:Cyclopentanes / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D019416:Head Movements / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000503:physiopathology; D009043:Motor Activity / Q000187:drug effects; D009270:Naloxone / Q000494:pharmacology / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000209:etiology*; D013997:Time Factors; D014202:Tremor / Q000188:drug therapy / Q000209:etiology; D014233:Tricarboxylic Acids / Q000494:pharmacology* / Q000627:therapeutic use
C409063:1-aminocyclopentane-1,2,4-tricarboxylic acid; D003517:Cyclopentanes; D009292:Narcotic Antagonists; D018094:Receptors, Metabotropic Glutamate; D014233:Tricarboxylic Acids; C102718:metabotropic glutamate receptor 3; D009270:Naloxone; D009020:Morphine